RET抑制剂TPX-0046治疗肿瘤,I/II期SWORD-1期研究已取得初步临床数据

2021-04-06 Allan MedSci原创

在5例未行RET TKI的患者中,有4例显示肿瘤消退率为-42%、-37%、-23%和-3%。在9例接受TKI治疗的患者中,有3例患者的肿瘤消退率为-44%、-27%和-17%。

Turning Point Therapeutics是一家精密肿瘤学公司,致力于开发针对癌症遗传驱动力的下一代疗法,Turning Point Therapeutics今天报告了正在进行的RET抑制剂TPX-0046的I/II期SWORD-1期研究的初步临床数据。

该研究的I期剂量寻找部分的初步数据显示出初步的临床活性,包括客观反应和普遍耐受良好的安全性。Turning Point Therapeutics继续评估剂量和时间表,以确定II期剂量,并计划修订研究方案。

纪念斯隆·凯特琳医院癌症中心早期药物开发服务部总经理Alexander Drilon说:“在美国和欧盟,每年由RET驱动的癌症会影响到近10,000名患者,而使用选择性RET抑制剂治疗后进展的患者仍然得不到足够的治疗。TPX-0046的初步数据令人鼓舞,其总体安全性和有效性良好”。

纳入研究的21位患者包括10例非小细胞肺癌(NSCLC)和11例甲状腺髓样癌(MTC)。所有16名接受TKI(酪氨酸激酶抑制剂)治疗的患者先前均接受了选择性RET TKI治疗,而9名患者(56%)接受了1种以上的TKI治疗。91%(19/21)的患者的ECOG基线表现评分为1,近一半(10/21)的患者接受了3种或更多的先前疗法。

在5例未行RET TKI的患者中,有4例显示肿瘤消退率为-42%、-37%、-23%和-3%。在9例接受TKI治疗的患者中,有3例患者的肿瘤消退率为-44%、-27%和-17%。

 

原始出处:

https://www.firstwordpharma.com/node/1815966?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2016759, encodeId=91a02016e59fc, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Fri Mar 11 17:48:12 CST 2022, time=2022-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020005, encodeId=bec820200051a, content=<a href='/topic/show?id=365518e5883' target=_blank style='color:#2F92EE;'>#Word#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18758, encryptionId=365518e5883, topicName=Word)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Tue Sep 07 19:48:12 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852631, encodeId=4c4618526316e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Dec 06 14:48:12 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913948, encodeId=ffbd191394830, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Wed Sep 15 02:48:12 CST 2021, time=2021-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561939, encodeId=876e156193971, content=<a href='/topic/show?id=56e7153908a' target=_blank style='color:#2F92EE;'>#RET抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15390, encryptionId=56e7153908a, topicName=RET抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Apr 08 13:48:12 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954918, encodeId=91e095491857, content=已看,还可以。, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 16:15:06 CST 2021, time=2021-04-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2016759, encodeId=91a02016e59fc, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Fri Mar 11 17:48:12 CST 2022, time=2022-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020005, encodeId=bec820200051a, content=<a href='/topic/show?id=365518e5883' target=_blank style='color:#2F92EE;'>#Word#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18758, encryptionId=365518e5883, topicName=Word)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Tue Sep 07 19:48:12 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852631, encodeId=4c4618526316e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Dec 06 14:48:12 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913948, encodeId=ffbd191394830, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Wed Sep 15 02:48:12 CST 2021, time=2021-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561939, encodeId=876e156193971, content=<a href='/topic/show?id=56e7153908a' target=_blank style='color:#2F92EE;'>#RET抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15390, encryptionId=56e7153908a, topicName=RET抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Apr 08 13:48:12 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954918, encodeId=91e095491857, content=已看,还可以。, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 16:15:06 CST 2021, time=2021-04-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2016759, encodeId=91a02016e59fc, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Fri Mar 11 17:48:12 CST 2022, time=2022-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020005, encodeId=bec820200051a, content=<a href='/topic/show?id=365518e5883' target=_blank style='color:#2F92EE;'>#Word#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18758, encryptionId=365518e5883, topicName=Word)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Tue Sep 07 19:48:12 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852631, encodeId=4c4618526316e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Dec 06 14:48:12 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913948, encodeId=ffbd191394830, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Wed Sep 15 02:48:12 CST 2021, time=2021-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561939, encodeId=876e156193971, content=<a href='/topic/show?id=56e7153908a' target=_blank style='color:#2F92EE;'>#RET抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15390, encryptionId=56e7153908a, topicName=RET抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Apr 08 13:48:12 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954918, encodeId=91e095491857, content=已看,还可以。, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 16:15:06 CST 2021, time=2021-04-07, status=1, ipAttribution=)]
    2021-12-06 jklm09
  4. [GetPortalCommentsPageByObjectIdResponse(id=2016759, encodeId=91a02016e59fc, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Fri Mar 11 17:48:12 CST 2022, time=2022-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020005, encodeId=bec820200051a, content=<a href='/topic/show?id=365518e5883' target=_blank style='color:#2F92EE;'>#Word#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18758, encryptionId=365518e5883, topicName=Word)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Tue Sep 07 19:48:12 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852631, encodeId=4c4618526316e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Dec 06 14:48:12 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913948, encodeId=ffbd191394830, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Wed Sep 15 02:48:12 CST 2021, time=2021-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561939, encodeId=876e156193971, content=<a href='/topic/show?id=56e7153908a' target=_blank style='color:#2F92EE;'>#RET抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15390, encryptionId=56e7153908a, topicName=RET抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Apr 08 13:48:12 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954918, encodeId=91e095491857, content=已看,还可以。, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 16:15:06 CST 2021, time=2021-04-07, status=1, ipAttribution=)]
    2021-09-15 ysjykql
  5. [GetPortalCommentsPageByObjectIdResponse(id=2016759, encodeId=91a02016e59fc, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Fri Mar 11 17:48:12 CST 2022, time=2022-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020005, encodeId=bec820200051a, content=<a href='/topic/show?id=365518e5883' target=_blank style='color:#2F92EE;'>#Word#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18758, encryptionId=365518e5883, topicName=Word)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Tue Sep 07 19:48:12 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852631, encodeId=4c4618526316e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Dec 06 14:48:12 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913948, encodeId=ffbd191394830, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Wed Sep 15 02:48:12 CST 2021, time=2021-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561939, encodeId=876e156193971, content=<a href='/topic/show?id=56e7153908a' target=_blank style='color:#2F92EE;'>#RET抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15390, encryptionId=56e7153908a, topicName=RET抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Apr 08 13:48:12 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954918, encodeId=91e095491857, content=已看,还可以。, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 16:15:06 CST 2021, time=2021-04-07, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2016759, encodeId=91a02016e59fc, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Fri Mar 11 17:48:12 CST 2022, time=2022-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020005, encodeId=bec820200051a, content=<a href='/topic/show?id=365518e5883' target=_blank style='color:#2F92EE;'>#Word#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18758, encryptionId=365518e5883, topicName=Word)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Tue Sep 07 19:48:12 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852631, encodeId=4c4618526316e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Dec 06 14:48:12 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913948, encodeId=ffbd191394830, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Wed Sep 15 02:48:12 CST 2021, time=2021-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561939, encodeId=876e156193971, content=<a href='/topic/show?id=56e7153908a' target=_blank style='color:#2F92EE;'>#RET抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15390, encryptionId=56e7153908a, topicName=RET抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Apr 08 13:48:12 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954918, encodeId=91e095491857, content=已看,还可以。, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 16:15:06 CST 2021, time=2021-04-07, status=1, ipAttribution=)]
    2021-04-07 ms6000001015893838

    已看,还可以。

    0

相关资讯

Nature Genetics:工欲善其事,必先利其器!新型单细胞技术揭示免疫检查点调节新机制

新研究推出了一种强大的分析技术,将极大的推动未来多模式单细胞研究。

梅斯肿瘤速递(第001期)

2021.3.26 梅斯肿瘤进展速览

Nat Commun:深度学习助力组织病理鉴定

研究人员的方法利用来自5700个样本的160万个认证病理学家的注释,来训练用于细胞和组织分类的深度学习模型,这些模型可以详尽地映射2和4微米分辨率的全玻片图像。

梅斯肿瘤速递(第002期)

梅斯医学将定期进行汇总,帮助大家概览肿瘤领域最新进展。

拓展阅读

无路可走的抉择,广谱抗癌药安罗替尼联合化疗让患者再次受益!

在这一项二期临床研究中,一线铂类治疗失败的晚期非小细胞肺癌被纳入研究,这些患者按照等比例分组。治疗组患者接受安罗替尼联合多西他赛,对照组则使用多西他赛单药治疗。

ELCC 2024 :接受根治性放射治疗的局部晚期非小细胞肺癌患者的心脏成像:CARERT 的初步结果

这项初步研究结果强调了心脏成像在评估积极治疗的局部晚期非小细胞肺癌中的临床意义。即使是临床无症状的患者,心脏成像也有助于发现心脏风险,从而预防不良心脏状况的发生。

ELCC 2024 :EGFR和TP53双突变对非小细胞肺癌治疗和预后有着重要影响: 韩国回顾性队列研究

该研究结果显示,相比仅携带EGFR突变的患者,携带TP53突变的晚期EGFR突变NSCLC患者有更短的治疗终止治疗时间。

引领肺癌治疗新潮流 | ELCC 2024看点解析别错过!

欧洲肺癌大会(ELCC)作为肺癌领域的顶级盛会,每年都汇聚全球顶尖专家,探讨最新研究进展。本文将为您揭秘本次大会的看点,及更多肺癌优质内容供您查看学习。

ELCC 2024 :一线奥希替尼联合铂类-培美曲塞化疗对比单用奥希替尼治疗EGFRm 晚期 NSCLC 的安全性和耐受性:来自 FLAURA2 研究数据

欧洲肺癌大会(ELCC)是肺癌领域的重要国际学术会议之一,近期2024年欧洲肺癌大会(ELCC 2024)在捷克布拉格线下与线上拉开帷幕,作为肺癌领域最大、最具影响力和代表性的国际学术会议,全球肺癌领

ELCC 2024 :奥希替尼在中国真实世界非小细胞肺癌(NSCLC)患者中的安全性

在这项针对中国临床实践中接受奥希替尼治疗的NSCLC患者的最大规模研究中,奥希替尼的耐受性良好,未发现新的安全信号。